| Literature DB >> 30901021 |
Mathieu Bastard1, Lucas Molfino2, Cláudia Mutaquiha3, Miriam Arago Galindo2, Pereira Zindoga3, Deise Vaz2, Ivan Mahinça3, Philipp DuCros4, Barbara Rusch2, Alex Telnov2.
Abstract
Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.Entities:
Keywords: bedaquiline; injectable drugs; multidrug-resistant tuberculosis; short regimen; treatment outcomes
Year: 2019 PMID: 30901021 DOI: 10.1093/cid/ciz196
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079